CN105477639A - 药物组合物 - Google Patents

药物组合物 Download PDF

Info

Publication number
CN105477639A
CN105477639A CN201510876678.0A CN201510876678A CN105477639A CN 105477639 A CN105477639 A CN 105477639A CN 201510876678 A CN201510876678 A CN 201510876678A CN 105477639 A CN105477639 A CN 105477639A
Authority
CN
China
Prior art keywords
compound
formula
insulin
diabetes
diabetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201510876678.0A
Other languages
English (en)
Chinese (zh)
Inventor
高桥祯介
S.内田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taisho Pharmaceutical Co Ltd
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Publication of CN105477639A publication Critical patent/CN105477639A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201510876678.0A 2009-04-16 2010-04-16 药物组合物 Pending CN105477639A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009100210 2009-04-16
JP2009-100210 2009-04-16
CN2010800169522A CN102395364A (zh) 2009-04-16 2010-04-16 药物组合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2010800169522A Division CN102395364A (zh) 2009-04-16 2010-04-16 药物组合物

Publications (1)

Publication Number Publication Date
CN105477639A true CN105477639A (zh) 2016-04-13

Family

ID=42982643

Family Applications (7)

Application Number Title Priority Date Filing Date
CN201510876708.8A Pending CN105343060A (zh) 2009-04-16 2010-04-16 药物组合物
CN201510876753.3A Pending CN105434430A (zh) 2009-04-16 2010-04-16 药物组合物
CN2010800169522A Pending CN102395364A (zh) 2009-04-16 2010-04-16 药物组合物
CN201510876678.0A Pending CN105477639A (zh) 2009-04-16 2010-04-16 药物组合物
CN201510876712.4A Pending CN105343871A (zh) 2009-04-16 2010-04-16 药物组合物
CN201510876636.7A Pending CN105343059A (zh) 2009-04-16 2010-04-16 药物组合物
CN201510876739.3A Pending CN105343880A (zh) 2009-04-16 2010-04-16 药物组合物

Family Applications Before (3)

Application Number Title Priority Date Filing Date
CN201510876708.8A Pending CN105343060A (zh) 2009-04-16 2010-04-16 药物组合物
CN201510876753.3A Pending CN105434430A (zh) 2009-04-16 2010-04-16 药物组合物
CN2010800169522A Pending CN102395364A (zh) 2009-04-16 2010-04-16 药物组合物

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN201510876712.4A Pending CN105343871A (zh) 2009-04-16 2010-04-16 药物组合物
CN201510876636.7A Pending CN105343059A (zh) 2009-04-16 2010-04-16 药物组合物
CN201510876739.3A Pending CN105343880A (zh) 2009-04-16 2010-04-16 药物组合物

Country Status (30)

Country Link
US (1) US20120040898A1 (enExample)
EP (3) EP2419097B1 (enExample)
JP (4) JP5077786B2 (enExample)
KR (2) KR20120016051A (enExample)
CN (7) CN105343060A (enExample)
AR (1) AR076317A1 (enExample)
AU (1) AU2010237748B2 (enExample)
BR (1) BRPI1012539A2 (enExample)
CA (1) CA2755392A1 (enExample)
CY (2) CY1114703T1 (enExample)
DK (2) DK2601949T3 (enExample)
ES (2) ES2523408T3 (enExample)
HK (6) HK1217301A1 (enExample)
HR (2) HRP20131120T1 (enExample)
ME (2) ME02015B (enExample)
MX (1) MX2011010901A (enExample)
MY (3) MY182720A (enExample)
NZ (4) NZ606888A (enExample)
PH (3) PH12015500235B1 (enExample)
PL (2) PL2601949T3 (enExample)
PT (2) PT2601949E (enExample)
RS (2) RS53761B1 (enExample)
RU (2) RU2532330C2 (enExample)
SG (6) SG2014014807A (enExample)
SI (2) SI2601949T1 (enExample)
SM (1) SMT201500015B (enExample)
TW (3) TW201103534A (enExample)
UA (2) UA105216C2 (enExample)
WO (1) WO2010119990A1 (enExample)
ZA (1) ZA201106727B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
WO2011039108A2 (en) 2009-09-30 2011-04-07 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives
UY32919A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
US20120283169A1 (en) * 2010-11-08 2012-11-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
TR201101809A1 (tr) * 2010-12-21 2012-07-23 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Vildagliptin ve glimepirid kombinasyonları.
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
ES2878001T3 (es) 2012-05-17 2021-11-18 Vtv Therapeutics Llc Composiciones del activador de la glucocinasa para el tratamiento de la diabetes
US9320727B2 (en) * 2012-08-30 2016-04-26 Taisho Pharmaceutical Co., Ltd Combinations of SGLT 2 inhibitors and antihypertensive drugs
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
PT2981271T (pt) 2013-04-05 2019-02-19 Boehringer Ingelheim Int Utilizações terapêuticas de empagliflozina
HK1213818A1 (zh) 2013-04-05 2016-07-15 勃林格殷格翰国际有限公司 依帕列净的治疗用途
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
EA033286B1 (ru) 2013-04-18 2019-09-30 Бёрингер Ингельхайм Интернациональ Гмбх Способ лечения или отсрочки развития хронической болезни почек
TW201636015A (zh) * 2013-07-05 2016-10-16 卡地拉保健有限公司 協同性組成物
JP6467583B2 (ja) * 2015-02-27 2019-02-13 ジ アサン ファウンデーション Ｄｐｐ−４の抑制剤を含む弁膜石灰化の予防または治療用の組成物
CN105963280B (zh) * 2016-06-30 2018-11-06 合肥华方医药科技有限公司 一种伏格列波糖口腔速溶膜及其制备方法
EP3528800A1 (en) 2016-10-19 2019-08-28 Boehringer Ingelheim International GmbH Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
JP7625363B2 (ja) 2016-11-10 2025-02-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬組成物、治療方法及びその使用
JP7066209B2 (ja) * 2016-11-14 2022-05-13 高雄醫學大學 糖代謝異常の検出方法と予防及び治療
CN111989103A (zh) 2018-04-17 2020-11-24 勃林格殷格翰国际有限公司 药物组合物、其治疗方法和用途
KR20190137343A (ko) 2018-06-01 2019-12-11 김유찬 계량 인덕션
CA3093025A1 (en) 2018-06-12 2019-12-19 Vtv Therapeutics Llc Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
MY206745A (en) 2018-10-29 2025-01-04 Boehringer Ingelheim Int Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
JP7425793B2 (ja) 2018-10-29 2024-01-31 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピリジニルスルホンアミド誘導体、医薬組成物およびそれらの使用
WO2021167840A1 (en) 2020-02-18 2021-08-26 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101103013A (zh) * 2005-01-07 2008-01-09 大正制药株式会社 1-硫代-d-葡萄糖醇衍生物
WO2008072726A1 (ja) * 2006-12-14 2008-06-19 Taisho Pharmaceutical Co., Ltd. １－フェニル １－チオ－ｄ－グルシト－ル誘導体

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4432757A1 (de) 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
JP2003520759A (ja) 1999-08-31 2003-07-08 アンドルックス ファーマスーティカルズ インコーポレーテッド 単位核を有する徐放性錠剤
EP2065044A1 (en) 2001-04-04 2009-06-03 Ortho-McNeil-Janssen Pharmaceuticals, Inc. Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators
CA2444481A1 (en) * 2001-04-11 2002-10-24 Bristol-Myers Squibb Company Amino acid complexes of c-aryl glucosides for treatment of diabetes and method
CN101479254B (zh) * 2006-06-29 2012-05-30 大正制药株式会社 C-苯基1-硫代山梨醇化合物
JP5194588B2 (ja) * 2006-07-06 2013-05-08 大正製薬株式会社 １−チオ−ｄ−グルシトール誘導体を有効成分として含有する糖尿病の予防又は治療剤
US8039441B2 (en) * 2006-08-15 2011-10-18 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as SGLT inhibitors and process for their manufacture
CL2007003227A1 (es) * 2006-11-09 2008-07-04 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo en combinacion con uno o mas agentes terapeuticos; y uso para el tratamiento de diabetes mellitus, obesidad e hiperglucemia entre otras.
PE20090938A1 (es) 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
PE20090603A1 (es) 2007-08-16 2009-06-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de sglt2 y un inhibidor de dpp iv

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101103013A (zh) * 2005-01-07 2008-01-09 大正制药株式会社 1-硫代-d-葡萄糖醇衍生物
WO2008072726A1 (ja) * 2006-12-14 2008-06-19 Taisho Pharmaceutical Co., Ltd. １－フェニル １－チオ－ｄ－グルシト－ル誘導体

Also Published As

Publication number Publication date
BRPI1012539A2 (pt) 2016-03-29
KR20150046382A (ko) 2015-04-29
EP2601949A3 (en) 2013-09-18
TW201622720A (zh) 2016-07-01
HK1218881A1 (zh) 2017-03-17
JP5910711B2 (ja) 2016-04-27
SG2014012405A (en) 2014-05-29
PH12019500959A1 (en) 2020-06-29
EP2829271A2 (en) 2015-01-28
HRP20141080T1 (hr) 2015-01-02
EP2419097A1 (en) 2012-02-22
AR076317A1 (es) 2011-06-01
PL2419097T3 (pl) 2014-02-28
MY182720A (en) 2021-02-03
UA111742C2 (uk) 2016-06-10
RU2014121260A (ru) 2015-12-10
ME01555B (me) 2014-04-20
MY183793A (en) 2021-03-16
SG2014015093A (en) 2014-04-28
AU2010237748B2 (en) 2014-10-30
NZ595314A (en) 2013-03-28
RS53056B (sr) 2014-04-30
MX2011010901A (es) 2011-11-01
CY1115907T1 (el) 2017-01-25
DK2601949T3 (da) 2015-01-05
CN102395364A (zh) 2012-03-28
CN105343880A (zh) 2016-02-24
RU2532330C2 (ru) 2014-11-10
HRP20131120T1 (hr) 2013-12-20
JP2016104775A (ja) 2016-06-09
RU2011146335A (ru) 2013-05-27
JP2015063543A (ja) 2015-04-09
HK1217434A1 (zh) 2017-01-13
JP5077786B2 (ja) 2012-11-21
EP2419097A4 (en) 2012-09-05
CA2755392A1 (en) 2010-10-21
HK1218871A1 (zh) 2017-03-17
CY1114703T1 (el) 2016-10-05
PH12019500961A1 (en) 2020-08-03
NZ710575A (en) 2016-06-24
CN105434430A (zh) 2016-03-30
KR20120016051A (ko) 2012-02-22
SI2419097T1 (sl) 2014-01-31
JP2012524710A (ja) 2012-10-18
SG2014012553A (en) 2014-05-29
EP2419097B1 (en) 2013-09-25
EP2601949A2 (en) 2013-06-12
ES2523408T3 (es) 2014-11-25
JP2013006854A (ja) 2013-01-10
PH12015500235A1 (en) 2015-12-02
SG2014012462A (en) 2014-05-29
UA105216C2 (en) 2014-04-25
WO2010119990A1 (en) 2010-10-21
NZ606888A (en) 2014-07-25
PL2601949T3 (pl) 2015-04-30
CN105343060A (zh) 2016-02-24
JP5660094B2 (ja) 2015-01-28
PT2601949E (pt) 2014-11-12
TW201500043A (zh) 2015-01-01
SG2014014807A (en) 2014-05-29
DK2419097T3 (da) 2013-10-28
NZ623838A (en) 2015-09-25
RS53761B1 (sr) 2015-06-30
CN105343059A (zh) 2016-02-24
JP6066144B2 (ja) 2017-01-25
HK1217435A1 (zh) 2017-01-13
PH12015500235B1 (en) 2015-12-02
EP2829271A3 (en) 2015-05-27
EP2601949B1 (en) 2014-10-29
MY156679A (en) 2016-03-15
TW201103534A (en) 2011-02-01
US20120040898A1 (en) 2012-02-16
SMT201500015B (it) 2015-03-05
SG175154A1 (en) 2011-11-28
SI2601949T1 (sl) 2014-12-31
PH12019500959B1 (en) 2020-06-29
PT2419097E (pt) 2013-10-03
PH12019500961B1 (en) 2020-08-03
CN105343871A (zh) 2016-02-24
ES2431300T3 (es) 2013-11-25
HK1217302A1 (zh) 2017-01-06
ME02015B (me) 2015-05-20
ZA201106727B (en) 2012-11-28
AU2010237748A1 (en) 2011-10-20
HK1217301A1 (zh) 2017-01-06

Similar Documents

Publication Publication Date Title
CN105477639A (zh) 药物组合物
KR101694136B1 (ko) Ｓｇｌｔ２ 억제제, ｄｐｐ－ｉｖ 억제제 및 임의로 추가의 당뇨병 치료제를 포함하는 약제학적 조성물 및 이의 용도
JP2018184441A (ja) ２型糖尿病の処置のためのリキシセナチド及びメトホルミン
JP2013540801A (ja) 代謝異常の治療のための組合せ医薬
TWI519297B (zh) 使用雙醋瑞因之糖尿病輔助療法
CN119997931A (zh) Obicetrapib和SGLT2抑制剂组合
AU2014221222B2 (en) Pharmaceutical compositions
HK1165292A (en) Pharmaceutical compositions
AU2016202866A1 (en) Pharmaceutical compositions
HK1161544A (en) Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
MX2009012310A (es) Metodo de tratamiento de diabetes tipo 2 que comprende terapia de adicion a metformina.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1218871

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160413

WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1218871

Country of ref document: HK